Answers are grounded in this paper and cite their sources.
Background: Chimeric antigen receptor (CAR) T-cell therapy has become an important treatment option for relapsed or refractory haematological malignancies. Its expanding use has increased attention to late adverse events, including secondary primary malignancies (SPMs). Aim: This narrative review summarises the reported clinical spectrum of SPMs after CAR-T therapy, considers potential mechanisms and risk factors, and outlines approaches to long-term monitoring. Methods: The review draws on the case reports, clinical studies, pharmacovigilance analyses, meta-analytic findings, and mechanistic studies discussed in the manuscript. Results: Reported SPMs include haematological malignancies, solid tumours, and non-melanoma skin cancers. A meta-analysis of 5,517 patients estimated an overall SPM frequency of 5.8%; haematological malignancies accounted for 37%, solid tumours for 27%, non-melanoma skin cancers for 16%, and T-cell malignancies for 1.5% of reported events. Other analyses identified secondary malignancies in 18 of 783 patients (2.3%) across 38 gene-modified T-cell therapy trials. Proposed mechanisms include vector integration and insertional mutagenesis, clonal selection, prior treatment-related genotoxicity, and impaired immune surveillance. The contribution of each mechanism remains uncertain, partly because molecular testing and follow-up have varied across studies. Conclusion: SPMs are uncommon but clinically important late events after CAR-T therapy. Current evidence supports continued surveillance and further investigation of long-term safety, while recognising that prior treatment exposures and underlying clonal abnormalities may also contribute to risk.
No takes yet. Share an insight, caveat, or question.
Xin et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: